SLC5A2 and type 2 diabetes mellitus: Importantly, SGLT2 inhibitors do not lead to drug-induced hypoglycemia in T2DM patients, and have also shown adjunctive effects in the management of hypertension, diabetic nephropathy, and lower risks of arrhythmias, and improved the bioavailability of endothelium-derived nitric oxide [10].